Other Events ·
REGENXBIO earns $100M milestone payment from AbbVie for sura-vec Phase IIb/III trial patient dosing
RGNXREGENXBIO Inc.
REGENXBIO Inc. announced on June 29, 2026, that it earned a $100.0 million milestone payment from AbbVie Global Enterprises Ltd. This payment stems from a Collaboration and License Agreement and is triggered by the dosing of the first patient in the Phase IIb/III clinical trial of surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy using suprachoroidal delivery. The company expects to receive the funds in July 2026. REGENXBIO Inc. is a biotechnology company focused on developing gene therapies.